References
- Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.
- Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60.
- Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035.
- Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515–522.
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884.
- Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukemia in FIP1L1-PDGFRA- expressing patients. Br J Haematol 2008; 141: 200–204.
- Pardanani A, D’Souza A, Knudson RA, et al. Long-term follow-up of FIP1L1-PDGFRA mutated patients with eosinophilia: survival and clinical outcome. Leukemia 2012; 26: 2439–2441.
- Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110: 3552–3556.
- Helbig G, Kyrcz-Krzemien S. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Am J Hematol 2014; 89: 115.
- Legrand F, Renneville A, Macintyre E, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. Medicine (Baltimore) 2013; [Epub ahead of print]. doi: 10.1097/MD.0b013e3182a71eba.
- Jovanovic J, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular response and achievement of complete molecular remission in FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Blood 2007; 109: 4635–4641.